19 studies found for:    HIV vaccine and NIAID | Open Studies
Show Display Options
Rank Status Study
1 Unknown  Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers
Condition: HIV Infections
Intervention: Biological: SCBaL/M9
2 Recruiting Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: NYVAC-HIV-PT1 vaccine;   Biological: NYVAC-HIV-PT4 vaccine;   Biological: Placebo for DNA-HIV-PT123 vaccine;   Biological: Placebo for NYVAC-HIV-PT1 vaccine;   Biological: Placebo for NYVAC-HIV-PT4 vaccine
3 Unknown  Controlling Acute or Early HIV Infection With Antiretroviral Drugs, With or Without a Candidate Vaccine
Condition: HIV Infections
Interventions: Biological: HIV-1 immunogen;   Biological: HIV-1 Immunogen
4 Recruiting Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: HIV-MAG vaccine;   Biological: IL-12 pDNA adjuvant;   Biological: VSV HIV gag vaccine;   Biological: Placebo
5 Recruiting Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals
Condition: HIV Infections
Interventions: Biological: VRC-HIVDNA-016-00-VP;   Biological: VRCHIVADV014-00-VP
6 Unknown  Resistance to HIV Infection
Condition: HIV Infections
Intervention:
7 Recruiting Therapeutic Vaccine for HIV
Conditions: HIV;   Therapeutic Vaccine
Interventions: Biological: HIV-1 Multiantigen pDNA Vaccine;   Biological: Human IL-12 pDNA;   Procedure: In Vivo Electroporation using the TriGri;   Biological: rVSVIN HIV Gag Vaccine;   Biological: Placebo
8 Recruiting Examining Factors That May Influence Resistance to HIV-1 Infection
Condition: HIV Infections
Intervention:
9 Recruiting Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected Mothers
Condition: HIV Infections
Interventions: Biological: RotaTeq vaccine;   Biological: RotaTeq vaccine placebo
10 Not yet recruiting Evaluating the Safety and Immune Response to Two Pneumococcal Vaccines in HIV-Infected Pregnant Women
Conditions: Pneumococcal Infections;   HIV Infections
Interventions: Biological: PPV-23 Vaccine;   Biological: PCV-13 Vaccine;   Biological: Placebo Vaccine
11 Recruiting Evaluating the Effectiveness of the Quadrivalent Human Papillomavirus (HPV) Vaccine at Preventing Anal HPV Infection in HIV-Infected Men and Women
Condition: HIV Infections
Interventions: Biological: Quadrivalent HPV Vaccine;   Biological: Placebo Vaccine for Male Participants Only;   Biological: Placebo Vaccine for Female Participants Only
12 Not yet recruiting Safety and Tolerability of a Therapeutic DNA Dendritic Cell Vaccine in HIV-Infected Children, Adolescents, and Young Adults
Condition: HIV Infections
Interventions: Biological: DermaVir patch;   Biological: Placebo patch
13 Recruiting Experimental AD4-H5-VTN Vaccine in Healthy Volunteers
Condition: H5N1 Influenza
Interventions: Biological: Ad4-H5-VTN vaccination-tonsillar route;   Biological: Ad4-H5-vaccination-oral route
14 Unknown  A Study of HIV-infected Subjects Initiating Anti-HIV Drugs for the First Time
Condition: HIV Infections
Intervention:
15 Recruiting Apheresis and Specimen Collection Procedures to Obtain Plasma, Peripheral Blood Mononuclear Cells (PBMCs) and Other Specimens for Research Studies
Condition: Blood Component Removal
Intervention:
16 Not yet recruiting Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants
Condition: Tuberculosis
Interventions: Biological: AERAS-404;   Biological: Placebo
17 Not yet recruiting Evaluating the Response to Three Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 28 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
Condition: HIV Infections
Interventions: Drug: Lamivudine/zidovudine;   Drug: Lopinavir/ritonavir;   Drug: Efavirenz;   Drug: Raltegravir
18 Recruiting Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in Men Who Have Sex With Men and in At-Risk Women
Condition: HIV Infection
Interventions: Drug: Maraviroc;   Drug: Emtricitabine;   Drug: Tenofovir disoproxil fumarate;   Other: Maraviroc placebo;   Other: Emtricitabine placebo;   Other: Tenofovir disoproxil fumarate placebo
19 Not yet recruiting Challenge Model for Assessment of Human TB Immunity
Condition: Mycobacterium Tuberculosis
Intervention: Biological: Tice® BCG

Indicates status has not been verified in more than two years